753010-14-9

Upstream product

• 937183-38-5 tert-butyl (3S,5S,6R)-3-(2-((RS)oxiran-2-yl)ethyl)-2-oxo-5,6-diphenylmorpholine-4-carboxylate 
• 869111-53-5 tert-butyl (3S,5S,6R)-3-[(3R)-3-hydroxy-4-bromo-butyl]-2-oxo-5,6-diphenyl-1,4-oxazinane-4-carboxylate 

Downstream Products

• 869111-58-0 C₅₇H₆₇N₃O₁₀ 
• 32619-23-1 (2S,5R)-2-amino-6[(2S,5S)-5-amino-5-carboxy-2-hydroxypentylamino]-5-hydroxyhexanoic acid 
• 869111-56-8 C₅₇H₆₇N₃O₁₀ 
• 869111-57-9 tert-butyl (3S,5S,6R)-3-[(3R)-4-benzylamino-3-hydroxybutyl]-2-oxo-5,6-diphenyl-1,4-oxazinane-4-carboxylate 
• 869111-55-7 (3S,5S,6R)-3-[(R)-4-((S)-5-Benzyloxycarbonylamino-5-tert-butoxycarbonyl-pentylamino)-3-hydroxy-butyl]-2-oxo-5,6-diphenyl-morpholine-4-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Reduced collagen cross links: The first synthesis of all the possible (2S,2′S)-stereoisomers of 5-hydroxylysinonorleucine and of 5,5′-dihydroxylysinonorleucine in enantiomerically pure form

The paper reports the first enantioselective synthesis of all the possible collagen reduced cross links as described: (2S,2′S,5R)- and (2S,2′S,5S)-5-hydroxylysinonorleucine 3a and 3b, (2S,2′S,5R, 5′R)-5,5′-dihydroxylysinonorleucine 4a, (2S,2′S,5R,5′S)- 5,